Semaglutide for Fatty Liver Disease: The MASH Trials That Are Reshaping Hepatology

The Disease Has a New Name — and a New Urgency

In 2023, a global expert consensus led by the American Association for the Study of Liver Diseases (AASLD) retired two widely used acronyms. What had been called NAFLD (non-alcoholic fatty liver disease) is now MASLD — metabolic-associated steatotic liver disease. What had been called NASH (non-alcoholic steatohepatitis) is now MASH — metabolic-associated steatohepatitis.

The rename was not cosmetic. The old terminology defined the disease by what it was not (non-alcoholic) rather than what it is: a metabolic condition tightly coupled to obesity, insulin resistance, and cardiovascular risk. The new nomenclature aligns the liver disease with the broader metabolic syndrome framework — and with the drugs, like GLP-1 receptor agonists, that treat it at its root.

The scale of the problem is staggering. An estimated 1.2 billion people globally have MASLD. In the United States alone, approximately 38 million Americans meet diagnostic criteria. It is the leading cause of liver transplant in people under 50, and its incidence is rising in lockstep with global obesity rates.

The Obesity–Liver Connection: How Fat Gets Into the Liver

The liver is downstream of adipose tissue — and when fat cells are overfull, they leak. In states of obesity and insulin resistance, adipose tissue releases excess free fatty acids (FFAs) into the portal circulation. The liver, acting as the body's metabolic clearinghouse, takes up this FFA flood. Some excess fat is packaged into VLDL and exported; the rest accumulates as triglycerides within hepatocytes, producing steatosis (fatty liver).

Simultaneously, insulin resistance drives a second pathway: de novo lipogenesis (DNL), where the liver synthesizes new fat directly from excess carbohydrates. When both pathways — FFA import and DNL — run at high capacity, the result is progressive hepatic fat accumulation even in the absence of high dietary fat intake.

This lipid overload sets off a cascade of oxidative stress, mitochondrial dysfunction, and inflammatory signaling that transforms simple steatosis into something far more dangerous.

Staging MASLD: From Fat to Cancer

The disease progresses through well-defined histological stages:

• Steatosis (S0–S3): Fat accumulation without inflammation. Often asymptomatic and can be identified on ultrasound or elevated liver enzymes. This stage alone does not drive significant clinical risk.
• MASH (formerly NASH): Inflammation, hepatocyte ballooning, and lobular inflammation superimposed on steatosis. This stage carries real risk of progression. Ballooning — a specific hepatocyte injury pattern — is the key pathological finding.
• Fibrosis (F1–F4): Activated hepatic stellate cells lay down collagen in response to chronic injury. Fibrosis stage is the dominant predictor of long-term outcome — not steatosis, not MASH activity score in isolation.
• Cirrhosis (F4): Replacement of liver architecture with scar tissue. Portal hypertension, varices, ascites, and hepatic encephalopathy follow.
• Hepatocellular carcinoma (HCC): MASLD-cirrhosis is now the fastest-growing cause of HCC in the United States. Six-monthly surveillance ultrasound + AFP is standard in cirrhosis.

The critical therapeutic insight: only MASH and early fibrosis are currently reversible. Once cirrhosis is established, the therapeutic window narrows dramatically. This is why the hepatology community is intensely focused on catching and treating MASH at F2–F3 fibrosis — precisely the patient population studied in the ESSENCE trial.

The LEAN Trial (2015): The First Signal

The story of GLP-1s in liver disease begins with a relatively small but methodologically rigorous trial published in The Lancet in 2015. Armstrong and colleagues randomized 52 patients with biopsy-proven NASH to liraglutide 1.8 mg/day or placebo for 48 weeks. All patients had NASH with or without fibrosis.

The results were remarkable for a trial of this size. 39% of liraglutide-treated patients achieved NASH resolution on repeat liver biopsy, compared to only 9% of placebo patients (P=0.02). Crucially, fibrosis non-progression was significantly higher in the treatment arm, and no patients on liraglutide experienced fibrosis worsening.

The LEAN trial was the first randomized controlled trial to demonstrate that a GLP-1 receptor agonist could reverse NASH on histology — the gold-standard outcome measure. It opened the door to larger, better-powered trials and attracted intense pharmaceutical interest in this mechanism for liver disease.

The ESSENCE Trial (2024): The Landmark

Nearly a decade after LEAN, the hepatology field got the definitive answer it needed. The ESSENCE trial, published in The New England Journal of Medicine in 2024 by Newsome and colleagues, enrolled 800 patients with biopsy-proven MASH and F2–F3 fibrosis — the population at highest risk of progression to cirrhosis and the clearest target for disease-modifying therapy.

Patients were randomized to semaglutide 2.4 mg/week (the Wegovy obesity dose, administered subcutaneously) or placebo, with 72 weeks of treatment followed by biopsy.

The primary endpoints and their results:

• MASH resolution without fibrosis worsening: 62.9% semaglutide vs 34.3% placebo — an absolute difference of nearly 29 percentage points
• Fibrosis improvement of one stage or more without MASH worsening: 37.0% semaglutide vs 22.4% placebo
• Both endpoints were statistically highly significant (P<0.001)
• ALT normalization occurred rapidly and sustained throughout the trial
• Body weight reduction of approximately 10% in the semaglutide arm contributed to, but did not fully explain, the hepatic benefit

The combination of MASH resolution AND fibrosis improvement in a single trial was unprecedented. No prior pharmacological agent — including vitamin E, pioglitazone, or obeticholic acid — had demonstrated this combination at this magnitude. The ESSENCE trial is now widely considered the most important result in MASH pharmacotherapy to date.

Why Does Semaglutide Work on the Liver?

The mechanisms by which semaglutide improves MASH histology are multiple and partially overlapping. The scientific debate centers on how much is direct hepatic action versus systemic metabolic improvement.

Indirect Mechanisms (Dominant Pathway)

• Weight loss reduces hepatic fat load: Every kilogram of body weight lost reduces hepatic fat content by roughly 1%. A 10% body weight reduction can clear substantial steatosis and reduce the inflammatory substrate driving MASH.
• Appetite suppression reduces dietary fat flux to liver: By slowing gastric emptying and reducing appetite, semaglutide limits the post-prandial surge of chylomicrons and FFAs entering the portal circulation.
• Adipose tissue remodeling: GLP-1 receptor activation in adipose tissue reduces adipose inflammation and improves adipokine profiles (higher adiponectin, lower leptin resistance). This reduces FFA efflux to the liver.
• Improved insulin sensitivity: Reduced systemic insulin resistance directly suppresses hepatic de novo lipogenesis — the liver stops manufacturing excess fat from carbohydrates.

Direct Hepatic Mechanisms (Emerging Evidence)

• Kupffer cell effects: Resident hepatic macrophages (Kupffer cells) express GLP-1 receptors and appear to reduce inflammatory cytokine production (TNF-α, IL-6) in response to GLP-1 agonism — potentially independent of weight change.
• Hepatocyte GLP-1 receptors: Controversial but emerging data suggests direct GLP-1 receptor signaling on hepatocytes modulates lipid metabolism. The receptor density is low relative to pancreatic islets or the gut, but may be functionally significant.
• Alcohol craving reduction: A notable observation from the SELECT cardiovascular trial was that semaglutide appeared to reduce alcohol consumption. In patients with metabolic-alcoholic fatty liver disease overlap, this may provide additional hepatic benefit beyond pure metabolic mechanisms.

ALT as an Early Biomarker

One of the most clinically useful early signals of semaglutide's hepatic effect is ALT normalization. In patients starting semaglutide for obesity or type 2 diabetes who have concurrent MASLD, ALT levels often fall dramatically within 8–12 weeks — frequently before meaningful weight loss has occurred. This suggests a direct or at least weight-independent anti-inflammatory effect on the liver.

In clinical practice, monitoring ALT at baseline and at 12 weeks serves as an early predictor of hepatic response. A substantial ALT drop (≥50% or normalization below 40 U/L) at 12 weeks correlates with improved steatosis on FibroScan and is a positive prognostic sign for longer-term histological benefit.

The FDA Approval Pathway and Resmetirom

Semaglutide does not yet carry an FDA-approved indication for MASH — but ESSENCE data places it on a clear regulatory pathway. Novo Nordisk has submitted for a MASH indication, and approval is widely anticipated in 2025.

Importantly, resmetirom (Rezdiffra) became the first-ever FDA-approved drug for MASH in March 2024 — just weeks before the ESSENCE results were published. Resmetirom is a selective thyroid hormone receptor-beta (THR-β) agonist that acts primarily on hepatic lipid metabolism. Its approval for MASH with F2–F3 fibrosis was based on the MAESTRO-NASH trial.

The existence of two complementary mechanisms (GLP-1 agonism + THR-β agonism) with overlapping but distinct targets has immediately generated interest in combination therapy. Combination trials are being designed; the hypothesis is that metabolic improvement via GLP-1 plus direct hepatic lipid-lowering via resmetirom may be additive.

Key Clinical Trial Evidence Summary

Monitoring Protocol for MASLD Patients on Semaglutide

Who Benefits Most?

Not every patient with elevated liver enzymes will benefit equally from semaglutide as MASH therapy. The evidence supports the strongest benefit in:

• Biopsy-proven MASH with F2–F3 fibrosis — the ESSENCE population; clearest indication for disease-modifying therapy
• Type 2 diabetes + obesity + elevated ALT — the overlap of indications means semaglutide treats the entire metabolic syndrome simultaneously
• MASLD without MASH — substantial steatosis reduction with weight loss benefits, though histological MASH reversal is the highest-value outcome
• Pre-cirrhotic patients — once cirrhosis is established, semaglutide may slow progression but cannot reverse architectural scarring

The patients least likely to benefit from semaglutide alone: those with established cirrhosis (F4), those with significant alcohol use overlap requiring separate management, and the 30–40% of patients with functional heartburn-like esophageal syndromes complicating GLP-1 tolerance.

References

1. Armstrong MJ, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679–690.
2. Loomba R, et al. Semaglutide 2.4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis. N Engl J Med. 2021; Phase 2 data.
3. Newsome PN, et al. Semaglutide 2.4 mg in patients with metabolic dysfunction-associated steatohepatitis (ESSENCE): a randomised, double-blind, placebo-controlled, phase 3 trial. N Engl J Med. 2024.
4. Harrison SA, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis (MAESTRO-NASH). N Engl J Med. 2023;389(6):497–509.
5. Rinella ME, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966–1986.